Literature DB >> 2360465

Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.

P Paoletti1, G Butti, R Knerich, P Gaetani, R Assietti.   

Abstract

In recent years, there has been a great improvement in the knowledge of the biological aspects of malignant gliomas of the brain. Conversely, there has been an increase of interest in the multimodal treatment of these tumours. In this review, we have analyzed the results of the several reports which have appeared in the literature that deal with the chemotherapeutic treatment of malignant gliomas. Furthermore, some areas of biological investigation that could have an impact on pharmacological therapy are discussed.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2360465     DOI： 10.1007/bf01420190

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN： 0001-6268            Impact factor:   2.216


  78 in total

Review 1.  The intraarterial route of drug delivery in the chemotherapy of malignant brain tumours.

Authors:  F Loew; L Papavero
Journal:  Adv Tech Stand Neurosurg       Date:  1988

2.  Increased O6-alkylguanine alkyltransferase activity in Chinese hamster V79 cells following selection with chloroethylating agents.

Authors:  J E Morten; G P Margison
Journal:  Carcinogenesis       Date:  1988-01       Impact factor: 4.944

3.  Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of the Scandinavian Glioblastoma Study Group.

Authors:  R Hatlevoll; K F Lindegaard; S Hagen; K Kristiansen; R Nesbakken; A Torvik; J C Ganz; O Mella; B Rosengren; R Ringkjöb
Journal:  Cancer       Date:  1985-07-01       Impact factor: 6.860

4.  Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma.

Authors:  J Maral; M Poisson; B F Pertuiset; P Mashaly; M Weil; C Jacquillat; A J Grillo-Lopez
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

5.  High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme.

Authors:  F H Hochberg; L M Parker; T Takvorian; G P Canellos; N T Zervas
Journal:  J Neurosurg       Date:  1981-04       Impact factor: 5.115

6.  Etoposide (VP-16-213) in malignant brain tumors: a phase II study.

Authors:  U Tirelli; M D'Incalci; R Canetta; S Tumolo; G Franchin; A Veronesi; E Galligioni; M G Trovò; C Rossi; E Grigoletto
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

7.  Comparison of bromodeoxyuridine labeling indices obtained from tissue sections and flow cytometry of brain tumors.

Authors:  T Nagashima; T Hoshino; K G Cho; M Senegor; F Waldman; K Nomura
Journal:  J Neurosurg       Date:  1988-03       Impact factor: 5.115

8.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

9.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.

Authors:  S B Green; D P Byar; M D Walker; D A Pistenmaa; E Alexander; U Batzdorf; W H Brooks; W E Hunt; J Mealey; G L Odom; P Paoletti; J Ransohoff; J T Robertson; R G Selker; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  Cancer Treat Rep       Date:  1983-02

10.  A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.

Authors:  M C Chamberlain; M D Prados; P Silver; V A Levin
Journal:  J Neurooncol       Date:  1988-12       Impact factor: 4.130
View more
  7 in total

1.  High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin.

Authors:  K W Albrecht; P C de Witt Hamer; S Leenstra; P J Bakker; J H Beijnen; D Troost; P Kaaijk; A D Bosch
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

2.  ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study.

Authors:  Ho-Shin Gwak; Sang-Min Youn; Austin-Hyuk Kwon; Seung Hoon Lee; Jong Hyun Kim; Chang Hun Rhee
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

3.  The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables.

Authors:  G Nikkhah; J C Tonn; O Hoffmann; H P Kraemer; J L Darling; W Schachenmayr; R Schönmayr
Journal:  J Neurooncol       Date:  1992-05       Impact factor: 4.130

4.  Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults.

Authors:  M Matsutani; O Nakamura; M Nakamura; T Nagashima; A Asai; T Fujimaki; H Tanaka; K Ueki; Y Tanaka
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Intra-operative radiation therapy for malignant brain tumors: rationale, method, and treatment results of cerebral glioblastomas.

Authors:  M Matsutani; O Nakamura; T Nagashima; A Asai; T Fujimaki; H Tanaka; M Nakamura; K Ueki; Y Tanaka; T Matsuda
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

6.  Intra-arterial cisplatin in malignant brain tumors: incidence and severity of otic toxicity.

Authors:  R Assietti; J J Olson
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

7.  Regulation of Inflammatory and Proliferative Pathways by Fotemustine and Dexamethasone in Endometriosis.

Authors:  Tiziana Genovese; Rosalba Siracusa; Ramona D'Amico; Marika Cordaro; Alessio Filippo Peritore; Enrico Gugliandolo; Rosalia Crupi; Angela Trovato Salinaro; Emanuela Raffone; Daniela Impellizzeri; Salvatore Cuzzocrea; Roberta Fusco; Rosanna Di Paola
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.